NASDAQ:MGNX - MacroGenics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $33.00
  • Forecasted Upside: 28.01 %
  • Number of Analysts: 7
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.61 (2.42%)

This chart shows the closing price for MGNX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New MacroGenics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MGNX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MGNX

Analyst Price Target is $33.00
▲ +28.01% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for MacroGenics in the last 3 months. The average price target is $33.00, with a high forecast of $41.00 and a low forecast of $17.00. The average price target represents a 28.01% upside from the last price of $25.78.

This chart shows the closing price for MGNX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 7 polled investment analysts is to buy stock in MacroGenics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 12 buy ratings
  • 1 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 12 buy ratings
  • 1 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/17/2021HC WainwrightReiterated RatingBuyLow
6/16/2021BTIG ResearchInitiated CoverageBuyMedium
6/7/2021WedbushLower Price TargetOutperform$39.00 ➝ $34.00High
4/30/2021SVB LeerinkBoost Price TargetOutperform$37.00 ➝ $40.00High
4/30/2021HC WainwrightBoost Price TargetBuy$36.00 ➝ $41.00High
4/26/2021Morgan StanleyBoost Price TargetUnderweight$16.00 ➝ $17.00N/A
4/19/2021Morgan StanleyBoost Price TargetUnderweight$15.00 ➝ $16.00Medium
3/12/2021BarclaysUpgradeUnderweight ➝ Overweight$14.00 ➝ $40.00High
3/4/2021Morgan StanleyBoost Price TargetUnderweight$14.00 ➝ $15.00N/A
2/26/2021Morgan StanleyBoost Price TargetUnderweight$14.00 ➝ $15.00High
12/22/2020HC WainwrightReiterated RatingBuy$36.00Low
12/17/2020BarclaysBoost Price TargetUnderweight$8.00 ➝ $14.00High
11/13/2020Morgan StanleyBoost Price TargetUnderweight$13.00 ➝ $14.00Low
11/5/2020SVB LeerinkLower Price TargetOutperform$38.00 ➝ $37.00High
10/13/2020Morgan StanleyBoost Price TargetUnderweight$12.00 ➝ $13.00Low
9/21/2020SVB LeerinkBoost Price TargetOutperform$35.00 ➝ $38.00High
8/3/2020CitigroupDowngradeBuy ➝ Neutral$25.00 ➝ $26.00High
7/31/2020Morgan StanleyBoost Price TargetUnderweight$11.00 ➝ $12.00High
7/31/2020HC WainwrightReiterated RatingBuy$40.00High
7/15/2020Morgan StanleyBoost Price TargetUnderweight$6.00 ➝ $11.00Low
6/2/2020CitigroupBoost Price Target$15.00 ➝ $25.00Low
6/1/2020GuggenheimUpgradeNeutral ➝ BuyLow
5/29/2020SVB LeerinkBoost Price TargetOutperform$15.00 ➝ $27.00Medium
5/29/2020Stifel NicolausBoost Price TargetBuy$21.00 ➝ $36.00High
5/28/2020BTIG ResearchBoost Price TargetBuy$23.00 ➝ $35.00High
5/26/2020HC WainwrightBoost Price TargetBuy$22.00 ➝ $40.00High
5/17/2020NomuraReiterated RatingBuy$50.00Low
5/14/2020WedbushBoost Price TargetOutperform$16.00 ➝ $28.00Medium
5/12/2020Credit Suisse GroupBoost Price TargetOutperform$13.00 ➝ $30.00High
5/6/2020WedbushReiterated RatingOutperformHigh
5/6/2020Credit Suisse GroupLower Price TargetOutperform$17.00 ➝ $13.00High
5/6/2020SVB LeerinkLower Price TargetOutperform$16.00 ➝ $15.00High
5/6/2020HC WainwrightBoost Price TargetBuy$18.00 ➝ $22.00High
3/4/2020BarclaysInitiated CoverageUnderweight$8.00Medium
3/2/2020Credit Suisse GroupLower Price TargetOutperform$26.00 ➝ $17.00Low
2/26/2020HC WainwrightReiterated RatingBuy$18.00High
2/26/2020Stifel NicolausLower Price TargetBuy$21.00 ➝ $20.00High
2/26/2020CitigroupLower Price TargetBuy$18.00 ➝ $15.00High
1/21/2020WedbushBoost Price TargetOutperform$14.00 ➝ $16.00High
12/20/2019HC WainwrightReiterated RatingBuy$18.00High
12/18/2019Cantor FitzgeraldInitiated CoverageOverweight$17.00Medium
12/12/2019BTIG ResearchReiterated RatingBuy ➝ Positive$23.00High
12/12/2019Nomura SecuritiesReiterated RatingBuy$50.00High
12/10/2019HC WainwrightReiterated RatingBuy$18.00High
12/10/2019CowenReiterated RatingBuyN/A
11/21/2019Morgan StanleyDowngradeEqual ➝ Equal Weight$17.00 ➝ $6.00High
11/20/2019GuggenheimInitiated CoverageHoldHigh
11/7/2019CitigroupLower Price TargetBuy$39.00 ➝ $18.00Low
10/23/2019HC WainwrightLower Price TargetBuy$39.00 ➝ $18.00High
10/23/2019SVB LeerinkLower Price TargetOutperform$26.00 ➝ $18.00High
10/23/2019WedbushLower Price TargetOutperform$23.00 ➝ $14.00High
8/1/2019Stifel NicolausLower Price TargetBuy$29.00 ➝ $25.00High
7/18/2019WedbushReiterated RatingOutperform$27.00Low
6/5/2019Morgan StanleySet Price TargetHold$19.00Low
6/5/2019Stifel NicolausLower Price TargetBuy$36.00 ➝ $29.00Low
6/5/2019WedbushReiterated RatingOutperform$26.00 ➝ $27.00High
6/5/2019CowenReiterated RatingBuyHigh
5/3/2019WedbushUpgradeNeutral ➝ Outperform$26.00Low
5/2/2019HC WainwrightReiterated RatingBuy$39.00High
5/2/2019CowenReiterated RatingBuyHigh
4/17/2019Credit Suisse GroupInitiated CoverageOutperform$29.00High
4/12/2019GuggenheimInitiated CoverageNeutralMedium
4/4/2019HC WainwrightReiterated RatingBuy$39.00Medium
2/20/2019HC WainwrightSet Price TargetBuy$39.00Low
2/7/2019Nomura SecuritiesBoost Price TargetBuy$41.00 ➝ $50.00Medium
2/7/2019SunTrust BanksBoost Price TargetBuy$40.00High
2/7/2019WedbushDowngradeOutperform ➝ NeutralHigh
2/7/2019CitigroupUpgradeSell ➝ Buy$10.00 ➝ $39.00High
2/6/2019Raymond JamesUpgradeUnderperform ➝ Market Perform$26.80High
2/6/2019HC WainwrightReiterated RatingPositive ➝ Buy$34.00 ➝ $39.00High
2/4/2019CitigroupDowngradeNeutral ➝ Sell$22.00 ➝ $10.00High
1/22/2019WedbushReiterated RatingOutperform ➝ Positive$44.00 ➝ $20.00High
1/21/2019Raymond JamesReiterated RatingSellHigh
12/10/2018Morgan StanleySet Price TargetHold$21.00High
12/10/2018Raymond JamesDowngradeOutperform ➝ UnderperformHigh
12/5/2018HC WainwrightSet Price TargetBuy$34.00High
11/29/2018HC WainwrightSet Price TargetBuy$34.00High
11/8/2018HC WainwrightSet Price TargetBuy$34.00High
10/30/2018HC WainwrightReiterated RatingBuy$34.00Medium
9/10/2018BTIG ResearchInitiated CoverageBuy ➝ Buy$30.00Low
8/8/2018CowenReiterated RatingBuyMedium
8/8/2018HC WainwrightReiterated RatingBuy$34.00High
6/4/2018HC WainwrightSet Price TargetBuy$34.00Low
5/31/2018Evercore ISIInitiated CoverageOutperform$33.00Medium
5/8/2018WedbushReiterated RatingOutperform$44.00High
5/8/2018HC WainwrightSet Price TargetBuy$34.00High
4/6/2018SVB LeerinkReiterated RatingOutperformHigh
3/14/2018Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$18.00 ➝ $26.00Medium
3/5/2018HC WainwrightInitiated CoverageBuy ➝ Buy$38.00High
1/24/2018CowenReiterated RatingBuyLow
1/23/2018SunTrust BanksReiterated RatingBuy$31.00High
1/23/2018BTIG ResearchReiterated RatingBuy$28.00High
12/11/2017Raymond JamesReiterated RatingBuyMedium
11/10/2017CitigroupBoost Price TargetNeutral$18.00 ➝ $22.00N/A
10/25/2017CowenReiterated RatingBuyN/A
9/12/2017Stifel NicolausReiterated RatingBuy$34.00High
9/11/2017WedbushReiterated RatingOutperform$44.00High
9/1/2017SunTrust BanksReiterated RatingBuy$26.00High
8/7/2017Morgan StanleyLower Price TargetEqual Weight$22.00 ➝ $21.00Low
8/4/2017CowenReiterated RatingBuyLow
5/8/2017Morgan StanleyLower Price TargetEqual Weight$24.00 ➝ $22.00Low
3/31/2017Raymond JamesInitiated CoverageOutperform ➝ Outperform$26.00High
3/6/2017BTIG ResearchReiterated RatingBuy$35.00 ➝ $28.00N/A
3/1/2017CowenReiterated RatingBuyN/A
3/1/2017Nomura InstinetInitiated CoverageBuy ➝ Buy$41.00N/A
3/1/2017Nomura SecuritiesInitiated CoverageBuyN/A
3/1/2017Roth CapitalSet Price TargetBuy$40.00N/A
3/1/2017Stifel NicolausReiterated RatingBuy$51.00 ➝ $42.00N/A
1/25/2017CitigroupLower Price TargetNeutral$32.00 ➝ $24.00N/A
12/19/2016SunTrust BanksInitiated CoverageBuy$30.00N/A
11/16/2016Roth CapitalReiterated RatingBuyN/A
11/7/2016BTIG ResearchReiterated RatingBuy$35.00N/A
11/3/2016WedbushReiterated RatingOutperform$52.00N/A
9/7/2016CowenInitiated CoverageOutperformN/A
8/4/2016CitigroupDowngradeBuy ➝ Neutral$27.00 ➝ $32.00N/A
(Data available from 7/23/2016 forward)
MacroGenics logo
MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics to treat cancer in the United States. The company's approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase II/III clinical trial for the treatment of breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3 for treating acute myeloid leukemia; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; Enoblituzumab, a monoclonal antibody that targets B7-H3; and Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3. In addition, it is developing MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company's non-immuno-oncology clinical product candidates include MGD014, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B Ã CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; Janssen Biotech, Inc.; and Alligator Bioscience AB (publ). The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
Read More

Today's Range

Now: $25.78
Low: $24.92
High: $25.91

50 Day Range

MA: $26.60
Low: $20.49
High: $32.19

52 Week Range

Now: $25.78
Low: $18.16
High: $36.48


242,322 shs

Average Volume

790,597 shs

Market Capitalization

$1.55 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of MacroGenics?

The following sell-side analysts have issued stock ratings on MacroGenics in the last twelve months: Barclays PLC, BTIG Research, Citigroup Inc., HC Wainwright, Morgan Stanley, SVB Leerink LLC, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for MGNX.

What is the current price target for MacroGenics?

6 Wall Street analysts have set twelve-month price targets for MacroGenics in the last year. Their average twelve-month price target is $33.00, suggesting a possible upside of 29.6%. HC Wainwright has the highest price target set, predicting MGNX will reach $41.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $17.00 for MacroGenics in the next year.
View the latest price targets for MGNX.

What is the current consensus analyst rating for MacroGenics?

MacroGenics currently has 1 sell rating, 1 hold rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MGNX will outperform the market and that investors should add to their positions of MacroGenics.
View the latest ratings for MGNX.

What other companies compete with MacroGenics?

How do I contact MacroGenics' investor relations team?

MacroGenics' physical mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The biopharmaceutical company's listed phone number is 301-251-5172. The official website for MacroGenics is